Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

879940.pdf (1.53 MB)

Document type

Article

Version

Published version

Publication date

2024-12-08

Publication license

cc-by (c) Almanza-Aguilera, E. et al., 2024
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219646

Prediagnostic plasma nutrimetabolomics and prostate cancer risk: a nested case–control analysis within the EPIC study 

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3390/cancers16234116

Abstract

Background and Objective: Nutrimetabolomics may reveal novel insights into early metabolic alterations and the role of dietary exposures on prostate cancer (PCa) risk. We aimed to prospectively investigate the associations between plasma metabolite concentrations and PCa risk, including clinically relevant tumor subtypes. Methods: We used a targeted and large-scale metabolomics approach to analyze plasma samples of 851 matched PCa case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Associations between metabolite concentrations and PCa risk were estimated by multivariate conditional logistic regression analysis. False discovery rate (FDR) was used to control for multiple testing correction. Results: Thirty-one metabolites (predominately derivatives of food intake and microbial metabolism) were associated with overall PCa risk and its clinical subtypes (p < 0.05), but none of the associations exceeded the FDR threshold. The strongest positive and negative associations were for dimethylglycine (OR = 2.13; 95% CI 1.16-3.91) with advanced PCa risk (n = 157) and indole-3-lactic acid (OR = 0.28; 95% CI 0.09-0.87) with fatal PCa risk (n = 57), respectively; however, these associations did not survive correction for multiple testing. Conclusions: The results from the current nutrimetabolomics study suggest that apart from early metabolic deregulations, some biomarkers of food intake might be related to PCa risk, especially advanced and fatal PCa. Further independent and larger studies are needed to validate our results.

Subject

Metabolisme, Nutrició, Càncer de pròstata

Subject (English)

Metabolism, Nutrition, Prostate cancer

Citation

Collections

Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

ALMANZA AGUILERA, Enrique, et al. Prediagnostic plasma nutrimetabolomics and prostate cancer risk: a nested case–control analysis within the EPIC study . Cancers. 2024. Vol. 16, num. 23. ISSN 2072-6694. [consulted: 11 of August of 2026]. Available at: https://hdl.handle.net/2445/219646

Export metadata

JSON - METS

Share record